Multiple host targets

The term Multiple host targets refers to a pharmacological classification where a therapeutic agent interacts with several distinct proteins or pathways within the host organism rather than a single specific molecular target. This concept is central to host-directed therapy (HDT), an approach primarily used in treating infectious diseases by modulating host cellular processes that pathogens exploit for replication or by enhancing the host's own immune defenses (Kaufmann et al., 2018, PubMed). By targeting multiple host factors, these drugs can potentially offer broad-spectrum activity against various viral or bacterial strains and significantly increase the genetic barrier to the development of pathogen resistance (Zumla et al., 2016, The Lancet Infectious Diseases). However, because this strategy involves the simultaneous modulation of various endogenous pathways, it often presents challenges in defining a precise mechanism of action and carries a higher risk of systemic toxicity or off-target effects. Common examples of drugs associated with multiple host targets include nitazoxanide, which affects various metabolic and signaling enzymes, and certain repurposed immunomodulators like chloroquine or statins (Rossignol, 2014, Antiviral Research). In drug discovery databases, this term is typically used as a collective category for agents whose clinical efficacy is derived from polypharmacology within the host.

Other names

Host-directed targetsHost factorsMultiple human targetsPolypharmacological host targets

Simultaneous modulation of multiple host cellular pathways, such as inhibiting host kinases, altering pH in endosomes, or activating innate immune signaling, to disrupt pathogen life cycles or reduce pathological inflammation.